Chiasma Inc. (CHMA) Stock Rating Lowered by Zacks Investment Research
Chiasma Inc. (NASDAQ:CHMA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday.
According to Zacks, “Chiasma, Inc. is a biopharmaceutical company. The company’s TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA. “
Shares of Chiasma (NASDAQ:CHMA) traded down 2.60% during mid-day trading on Tuesday, hitting $3.00. The stock had a trading volume of 146,267 shares. Chiasma has a 52-week low of $2.40 and a 52-week high of $24.78. The firm has a 50 day moving average price of $2.75 and a 200 day moving average price of $3.70. The firm’s market cap is $73.07 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/chiasma-inc-chma-stock-rating-lowered-by-zacks-investment-research.html
Chiasma (NASDAQ:CHMA) last announced its quarterly earnings data on Wednesday, August 10th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.47. Equities analysts predict that Chiasma will post ($3.14) EPS for the current year.
A number of hedge funds have recently bought and sold shares of CHMA. Franklin Resources Inc. boosted its stake in Chiasma by 32.5% in the first quarter. Franklin Resources Inc. now owns 807,440 shares of the company’s stock worth $7,396,000 after buying an additional 198,200 shares in the last quarter. Geode Capital Management LLC boosted its stake in Chiasma by 19.4% in the first quarter. Geode Capital Management LLC now owns 55,693 shares of the company’s stock worth $510,000 after buying an additional 9,038 shares in the last quarter. Wellington Management Group LLP boosted its stake in Chiasma by 1,074.0% in the first quarter. Wellington Management Group LLP now owns 1,245,265 shares of the company’s stock worth $11,406,000 after buying an additional 1,139,195 shares in the last quarter. Sphera Funds Management LTD. acquired a new stake in Chiasma during the first quarter worth $2,113,000. Finally, Opaleye Management Inc. acquired a new stake in Chiasma during the first quarter worth $183,000. Institutional investors own 58.76% of the company’s stock.
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.